The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

被引：0
|
作者：
Toshihiko Doi
Yutaka Fujiwara
Kohei Shitara
Toshio Shimizu
Kan Yonemori
Nobuaki Matsubara
Izumi Ohno
Takahiro Kogawa
Yoichi Naito
Lance Leopold
Mihaela Munteanu
Naoyoshi Yatsuzuka
Shi Rong Han
Ayman Samkari
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital East,Department of Experimental Therapeutics
[2] National Cancer Center Hospital,Department of Experimental Therapeutics
[3] Mitsui Memorial Hospital,Department of Respiratory Medicine
[4] Incyte Corporation,Department of Clinical Oncology
[5] Clinical Development,undefined
[6] MSD K.K. Oncology Science Unit,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
Investigational New Drugs | 2021年 / 39卷
关键词：
Advanced solid tumors; Epacadostat (INCB024360); Japanese; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：152 / 162
页数：10
相关论文
共 50 条
  • [31] Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer
    Tamura, Kenji
    Kodaira, Makoto
    Shimizu, Chikako
    Yonemori, Kan
    Yunokawa, Mayu
    Shimomura, Akihiko
    Kobayashi, Takayuki
    Nakano, Kenji
    Tomomatsu, Junichi
    Ito, Yoshinori
    Tanaka, Jun
    Kuriki, Hiroshi
    Gu, Zhaodi
    Takahashi, Shunji
    CANCER SCIENCE, 2018, 109 (05): : 1592 - 1601
  • [32] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    LoRusso, Patricia M.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    Cohen, Roger B.
    BMC CANCER, 2017, 17
  • [33] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Infante, Jeffrey R.
    Cohen, Roger B.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 576 - 588
  • [34] A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
    Patricia M. LoRusso
    Jeffrey R. Infante
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Roger B. Cohen
    BMC Cancer, 17
  • [35] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [36] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [37] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
  • [38] MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
    Vicier, C.
    Isambert, N.
    Cropet, C.
    Hamimed, M.
    Osanno, L.
    Legrand, F.
    Rouge, T. de La Motte
    Ciccolini, J.
    Goncalves, A.
    ESMO OPEN, 2022, 7 (06)
  • [39] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
    Hajime Asahina
    Yosuke Tamura
    Hiroshi Nokihara
    Noboru Yamamoto
    Yoshitaka Seki
    Takashi Shibata
    Yasushi Goto
    Maki Tanioka
    Yasuhide Yamada
    Andrew Coates
    Yi-Lin Chiu
    Xiaohui Li
    Rajendra Pradhan
    Peter J. Ansell
    Evelyn M. McKeegan
    Mark D. McKee
    Dawn M. Carlson
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1477 - 1486
  • [40] Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAFV600 mutation-positive solid tumors: a phase 1 study
    Yutaka Fujiwara
    Naoya Yamazaki
    Yoshio Kiyohara
    Shusuke Yoshikawa
    Noboru Yamamoto
    Arata Tsutsumida
    Hiroshi Nokihara
    Kenjiro Namikawa
    Akihira Mukaiyama
    Fanghong Zhang
    Tomohide Tamura
    Investigational New Drugs, 2018, 36 : 259 - 268
12345